3
Announcements
Trials
Browse
Landscape
Status
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Observational
2
Sponsor
Cancer Type
Endocrine
2
Conditions
Adrenal Gland Neoplasms
5
Adrenal incidentaloma
3
Pheochromocytoma
2
Hypertension
2
Cushing Syndrome
2
Urinary Bladder Neoplasms
1
Osteoporosis
1
Obesity
1
Hypokalemia
1
Hypercholesterolemia
1
Hyperaldosteronism
1
Diabetes Mellitus
1
Carcinoma, Renal Cell
1
Adrenocortical Carcinoma
1
Adrenocortical Adenoma
1
Interventions
3-Iodobenzylguanidine
14
Temozolomide
6
lutetium Lu 177 dotatate
5
gallium Ga 68 dotatate
4
anlotinib
4
Specimen Handling
4
Everolimus
4
Radiotherapy
3
Phenoxybenzamine
3
Magnetic Resonance Spectroscopy
3
Doxorubicin
3
6-fluorodopamine
3
3-fluorobenzylguanidine
3
pegfilgrastim
2
olaparib
2
fluorodopa F 18
2
cabozantinib
2
belzutifan
2
Nivolumab
2
Ifosfamide
2
Granulocyte Colony-Stimulating Factor
2
Fluorodeoxyglucose F18
2
Filgrastim
2
Doxazosin
2
Dexmedetomidine
2
Capecitabine
2
Biopsy
2
Axitinib
2
Adrenalectomy
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Pheochromocytoma
×
Adrenalectomy
×
Endocrine
×
Clear all
NCT07200245
2025-10-01
HEMODYNAMICS
Central Hospital, Nancy, France
Not yet recruiting
522 enrolled
NCT06062082
2025-02-13
HEMODADRE
Central Hospital, Nancy, France
Completed
60 enrolled